This supplement reviews two posters presented at the ‘Liver Meeting®’ 2021. Both posters delved into new trial data on the efficacy of Aramchol™ to treat non-alcoholic steatohepatitis, analysing biopsy outcomes, fibrosis improvement, and biomarker data.
Latest articles
All articles
7 Mins
23rd
January
Exploring Hepatocellular Carcinoma: Massimo Colombo
EMJ is thrilled to present an interview with Massimo Colombo, Past Professor of Gastroenterology at the University of Milan, Italy, that…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
6 Mins
24th
September
Diagnosis of progressive familial intrahepatic cholestasis in adulthood
Progressive familial intrahepatic cholestasis (PFIC) is a cholestatic condition that typically arises in childhood. As such, if an adult…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
3 Mins
18th
July
Interview: Mario Strazzabosco
The management of liver cancer has changed dramatically during the 4 decades since I started as an internal medicine speciality fellow…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
5 Mins
18th
July
Prevention of Decompensation in Compensated Cirrhosis
Portal hypertension is the major determinant of outcomes in patients with cirrhosis, defined as the presence of a hepatic venous pressure…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.